Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of AR098081A1publicationCriticalpatent/AR098081A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
En la presente se proporciona un anticuerpo anti-R-espondina (anti-RSPO), en particular anticuerpos anti-R-espondina 2 (anti-RSPO2) y/o anticuerpos anti-R-espondina 3 (anti-RSPO3), y métodos para su uso. Ácido nucleico; célula huésped; método para producir un anticuerpo; inmunoconjugado; formulación farmacéutica; método para tratar a un individuo.An anti-R-spondin (anti-RSPO) antibody, in particular anti-R-spondin 2 (anti-RSPO2) and / or anti-R-spondin 3 (anti-RSPO3) antibodies, and methods are provided herein, and methods for use Nucleic acid; host cell; method to produce an antibody; immunoconjugate; pharmaceutical formulation; method to treat an individual.
ARP140103886A2013-10-182014-10-17
ANTI-RSPO ANTIBODIES AND METHODS OF USE
AR098081A1
(en)
antibodies, nucleic acid, host cell, method for producing an antibody, pharmaceutical formulation, use of the antibody and method of treating an individual who has cancer
multispecific antibody, isolated antibody, isolated nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, antibody use and method of treating individuals with disorder
bispecific antibody, pharmaceutical composition, use of bispecific antibody, nucleic acid sequence, expression vector, host cell and method of producing an antibody
isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder
antibodies, nucleic acid, host cell, antibody production method, pharmaceutical formulation, antibody use, treatment method and activation method of a complex
hetero-multimer, isolated antibody construct, nucleic acid, host cell, method for preparing the hetero-multimer, pharmaceutical composition, method for treating a disease, use of the hetero-multimer, use of a therapeutic amount of the hetero-multimer, and method for reduce effector function of an antibody construct